Zyprexa Fines Irrelevant In Actos Trial, Eli Lilly Says

Law360, New York (March 7, 2014, 5:25 PM EST) -- Eli Lilly & Co. argued Thursday that the first federal bellwether trial over the bladder cancer risks of diabetes drug Actos should exclude evidence about its fines for marketing the antipsychotic drug Zyprexa, saying it’s not relevant to negligent marketing claims over Actos. 

In a response filed to the Louisiana federal court, Eli Lilly argued that the fines over Zyprexa stemmed from misdemeanor criminal violations, and not any finding of negligence. Its response followed a demand for sanctions earlier this week by plaintiffs Terrence and Susan...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Allen et al v. Takeda Pharmaceuticals North America Inc et al


Case Number

6:12-cv-00064

Court

Louisiana Western

Nature of Suit

Personal Inj. Prod. Liability

Judge

Rebecca F Doherty

Date Filed

January 17, 2012

Law Firms

Companies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.